[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1989

EtretinatePersistent Serum Levels After Long-term Therapy

Author Affiliations

From the Dermatology Branch (Drs DiGiovanna and Peck and Ms Gantt) and Laboratory of Mathematical Biology (Dr Zech), National Cancer Institute, and Clinical Chemistry (Dr Ruddel), Clinical Center, National Institutes of Health, Bethesda, Md.

Arch Dermatol. 1989;125(2):246-251. doi:10.1001/archderm.1989.01670140098019
Abstract

• In 47 patients who received long-term etretinate therapy, we measured serum etretinate concentrations from one to 244 weeks after the discontinuation of therapy. The earliest posttreatment, nondetectable serum concentration of etretinate was observed at five weeks after treatment. Detectable serum concentrations (0.05 to 1.2 μg/dL) were observed more than two years (108, 111, 131, 136, and 150 weeks) following the discontinuation of therapy. Sequential serum concentrations obtained on eight individual patients were used to determine half-lives for this late-phase elimination. The median half-life for the 12 curves obtained was 12.5 weeks (range, 5.3 to 24.8 weeks). Since etretinate is stored in fat, we compared each patient's deviation from ideal body weight as a measure of excess body fat with various pharmacokinetic factors of etretinate elimination. Overweight patients tended to have slower elimination, maintain higher serum concentrations, and clear etretinate later.

(Arch Dermatol 1989;125:246-251)

×